Bellecapital International Ltd. held its stake in shares of Sanofi SA (NYSE:SNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,340 shares of the company’s stock at the end of the second quarter. Bellecapital International Ltd.’s holdings in Sanofi SA were worth $352,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of SNY. Fisher Asset Management LLC boosted its stake in Sanofi SA by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares in the last quarter. Bank of America Corp DE boosted its stake in Sanofi SA by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Sanofi SA by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock worth $203,296,000 after buying an additional 815,820 shares in the last quarter. Brandes Investment Partners LP boosted its stake in Sanofi SA by 3.0% in the first quarter. Brandes Investment Partners LP now owns 3,490,226 shares of the company’s stock worth $157,933,000 after buying an additional 102,511 shares in the last quarter. Finally, Hamlin Capital Management LLC boosted its stake in Sanofi SA by 11.8% in the first quarter. Hamlin Capital Management LLC now owns 1,768,523 shares of the company’s stock worth $80,026,000 after buying an additional 186,280 shares in the last quarter. 9.97% of the stock is currently owned by institutional investors.
Sanofi SA (NYSE:SNY) opened at 47.56 on Friday. The company has a market capitalization of $120.11 billion, a P/E ratio of 11.47 and a beta of 0.89. Sanofi SA has a one year low of $36.81 and a one year high of $50.24. The stock’s 50 day moving average price is $48.14 and its 200-day moving average price is $45.66.
Sanofi SA (NYSE:SNY) last announced its quarterly earnings results on Friday, April 28th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.03. The company had revenue of $8.65 billion during the quarter, compared to analysts’ expectations of $8.40 billion. The company’s revenue was up 1.2% on a year-over-year basis. Equities analysts forecast that Sanofi SA will post $3.20 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2017/07/29/bellecapital-international-ltd-has-352000-position-in-sanofi-sa-nysesny.html.
A number of research firms have recently commented on SNY. Argus increased their target price on Sanofi SA from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 9th. TheStreet raised Sanofi SA from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Zacks Investment Research cut Sanofi SA from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. BidaskClub cut Sanofi SA from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, HSBC Holdings plc cut Sanofi SA from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $67.67.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.
